Corrigendum to “Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables” [Int. J. Mycobacteriol. 5(1) 2016 1-6]. Go to Publication You Might Also Like Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection August 30, 2019 Early bactericidal activity of new drug regimens for tuberculosis. January 12, 2013 COVID-19 care in India: the course to self-reliance September 3, 2020 Retrospective study of interstitial lung disease in a tertiary care centre in India. December 28, 2010 Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis. October 23, 2017
Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection August 30, 2019
Retrospective study of interstitial lung disease in a tertiary care centre in India. December 28, 2010
Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis. October 23, 2017